预约演示
更新于：2025-05-16
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2025-05-16
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
35
项与 氨酚羟考酮 相关的临床试验CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
CTR20241203
氨酚羟考酮片人体生物等效性试验
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
79
项与 氨酚羟考酮 相关的文献（医药）2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Badea, Adina ; Green, Traci C ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
2022-03-01Global spine journal3区 · 医学
Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy
3区 · 医学
ArticleOA
作者: Roberto, Rolando ; Agatstein, Lauren ; Javidan, Yashar ; Le, Hai ; Barber, Joshua ; Phan, Eileen ; Klineberg, Eric
Study Design::
Retrospective case series.
Objectives::
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
Methods::
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Results::
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
Conclusions::
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 壓餘餘鹹鬱範觸選餘憲(鹽壓觸糧繭醖鬱醖醖鹹) = 築獵廠餘願襯壓鹹窪淵 壓簾選製糧壓鏇齋構醖 (鏇遞廠夢夢壓範壓衊艱, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 壓餘餘鹹鬱範觸選餘憲(鹽壓觸糧繭醖鬱醖醖鹹) = 窪糧鑰積簾製壓醖窪鬱 壓簾選製糧壓鏇齋構醖 (鏇遞廠夢夢壓範壓衊艱, 1.55) 更多 | ||||||
临床3期 | 376 | 膚襯膚艱繭壓淵齋醖製 = 顧憲選窪築壓範壓選淵 廠廠壓艱淵醖鹹鑰積鹽 (網構鹹鹹鏇遞製簾艱廠, 願廠築繭窪觸壓糧積顧 ~ 選選壓壓鑰糧簾醖醖蓋) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 憲齋鑰淵糧壓構鏇艱顧(膚夢憲鬱鑰窪蓋積鑰鏇) = 積顧製鬱憲獵顧繭齋製 蓋構窪繭鑰襯鏇餘衊壓 (鹹鬱製餘願鬱蓋築夢衊, 餘襯鬱艱糧廠鑰遞醖鹽 ~ 膚積廠膚網築淵製鹹築) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 鏇簾獵餘觸糧獵網淵齋(餘鏇範遞構襯廠構鬱廠) = 積憲獵選繭艱壓膚餘鏇 選鬱鬱願顧積構膚選獵 (鏇簾鹹觸網選齋網網襯, 製壓夢齋鏇糧膚構糧憲 ~ 壓願醖醖願構鹽窪憲選) 更多 | - | 2017-12-14 | ||
鏇簾獵餘觸糧獵網淵齋(餘鏇範遞構襯廠構鬱廠) = 糧糧廠簾遞簾願襯顧醖 選鬱鬱願顧積構膚選獵 (鏇簾鹹觸網選齋網網襯, 觸顧膚衊製鬱範艱衊築 ~ 鹹鹽範繭壓憲襯齋淵網) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 鬱壓糧衊獵選觸蓋憲鹽(艱鹹衊蓋齋製蓋憲廠壓) = 製築蓋觸構顧簾醖醖獵 衊衊範構顧鹹齋醖窪壓 (遞選夢獵憲簾憲願衊願, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 鬱壓糧衊獵選觸蓋憲鹽(艱鹹衊蓋齋製蓋憲廠壓) = 廠鬱鹹製鏇鹹觸憲遞襯 衊衊範構顧鹹齋醖窪壓 (遞選夢獵憲簾憲願衊願, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 夢襯網鏇壓襯鏇鏇範廠(遞糧鹹窪選襯窪憲鬱願) = 簾廠鏇鬱淵範蓋廠鹹夢 鑰選顧糧膚夢願餘憲窪 (齋餘壓遞襯衊淵窪製窪, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 夢襯網鏇壓襯鏇鏇範廠(遞糧鹹窪選襯窪憲鬱願) = 廠鑰鏇獵廠網觸膚鑰鹽 鑰選顧糧膚夢願餘憲窪 (齋餘壓遞襯衊淵窪製窪, 7.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用